Price
CHART BY
Frequently asked questions
What is BiolineRX Ltd. Sponsored ADR's market capitalization?
The market capitalization of BiolineRX Ltd. Sponsored ADR is $11.97M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BiolineRX Ltd. Sponsored ADR?
BiolineRX Ltd. Sponsored ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.819. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BiolineRX Ltd. Sponsored ADR's stock?
Currently, 1 analysts cover BiolineRX Ltd. Sponsored ADR's stock, with a consensus target price of $22.00. Analyst ratings provide insights into the stock's expected performance.
What is BiolineRX Ltd. Sponsored ADR's revenue over the trailing twelve months?
Over the trailing twelve months, BiolineRX Ltd. Sponsored ADR reported a revenue of $1.40M.
What is the EBITDA for BiolineRX Ltd. Sponsored ADR?
BiolineRX Ltd. Sponsored ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$11.90M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BiolineRX Ltd. Sponsored ADR?
BiolineRX Ltd. Sponsored ADR has a free cash flow of -$10.88M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BiolineRX Ltd. Sponsored ADR have, and what sector and industry does it belong to?
BiolineRX Ltd. Sponsored ADR employs approximately 24 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of BiolineRX Ltd. Sponsored ADR's shares?
The free float of BiolineRX Ltd. Sponsored ADR is 4.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $11.97M
- EPS (TTM)
- -$1.819
- Free Float
- 4.34M
- Revenue (TTM)
- $1.40M
- EBITDA (TTM)
- -$11.90M
- Free Cashflow (TTM)
- -$10.88M
Pricing
- 52W span
- $2.16$4.52
Analyst Ratings
The price target is $22.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
- Employees
- 24
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- BLRX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet